Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: rgp120/HIV-1MN Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers

NCT00000868
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

NCT00001026
View directory record Official record
Conditions
HIV Infections
Interventions
gp160 Vaccine (Immuno-AG), rgp120/HIV-1IIIB, rgp120/HIV-1MN, rgp120/HIV-1 SF-2, HIVAC-1e
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1994
U.S. locations
2
States / cities
Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Safety and Immunogenicity Trial of UBI SynVac (HIV-1 MN Octameric V3 Peptide Vaccine)

NCT00000775
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)

NCT00001041
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 40 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
6
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

NCT00001052
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, QS-21, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
5
States / cities
St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

NCT00001031
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 60 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1997
U.S. locations
7
States / cities
Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3

NCT00000779
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, MF59, rgp120/HIV-1IIIB, rgp120/HIV-1MN, rgp120/HIV-1 SF-2, Env 2-3
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Jose, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Antigen in Children Born to HIV-Infected Mothers

NCT00000774
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2, Placebo version of rgp120/HIV-1MN, Placebo version of rgp120/HIV-1SF2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 3 Days
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
36
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3

NCT00000755
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, Zidovudine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)

NCT00001020
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1IIIB, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1995
U.S. locations
3
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

NCT00000762
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 18 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
33
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)

NCT00001021
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1IIIB, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
3
States / cities
St Louis, Missouri • Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults

NCT00000853
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1999
U.S. locations
3
States / cities
Birmingham, Alabama • Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

NCT00002428
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 Peptide Vaccine, Microparticulate Monovalent, rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
Biological
Lead sponsor
United Biomedical
Industry
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults

NCT00001096
View directory record Official record
Conditions
HIV Infections
Interventions
MN rgp120/HIV-1 and A244 rgp120/HIV-1, QS-21, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2000
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 5:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.

NCT00001044
View directory record Official record
Conditions
HIV Infections
Interventions
Aluminum hydroxide, QS-21, rgp120/HIV-1MN
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 1995
U.S. locations
4
States / cities
St Louis, Missouri • Rochester, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 23, 2026, 5:14 AM EDT